ERO1A and melanoma: To further investigate whether ERO1A expression was associated with better clinical outcomes in patients treated with immunotherapy, we collected transcriptome profiling combined with corresponding clinical data of ICI-treated patients with NSCLC (GEO: GSE190265) and melanoma (ENA: PRJEB23709).